CrystalGenomics rises 7.4% amid immune oncology theme uptrend

On the 11th, the immuno-oncology theme rose by 3.27% compared to the previous day, showing strong performance, while CrystalGenomics, a related stock attracting attention, surged by 7.4% compared to the previous day. CrystalGenomics is known as a company specializing in new drug development, including treatments for arthritis and novel antibiotics.

[Graph] Price Fluctuations of Major Stocks in the Immuno-Oncology Theme

According to provisional data compiled at 11:18, foreign investors have been heavily net buying CrystalGenomics, purchasing 52,100 shares.

[Table] Net Trading Volume of Foreign and Institutional Investors (Unit: 10,000 shares)

According to the analysis by Thinkpool RoboAlgorithm RASSI, CrystalGenomics’ quant financial score is 18.66 points, ranking 9th within the immuno-oncology theme due to higher growth and stability scores compared to the average of other related stocks. This indicates that, compared to other stocks in the theme, CrystalGenomics shows relatively rapid increases in sales and net income, as well as good responsiveness to changes in domestic and international economic environments.

[Table] Top Stocks by Financial Score within the Theme

※ The quant financial score is the result of RoboAlgorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, and other factors.

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.